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Acute pneumonia developed in a previously healthy
man during the outbreak of severe acute respiratory syn-
drome (SARS) in southern China in March 2003. Antibiotic
treatment was ineffective, and he died 8 days after illness
onset. Human metapneumovirus was isolated from lung tis-
sue. No other pathogen was found. Other etiologic agents
should thus be sought in apparent SARS cases when coro-
navirus infection cannot be confirmed. 
H
uman metapneumovirus (HMPV) is a newly identi-
fied member of the family Paramyxoviridae  (1).
HMPV infections have been found in all age groups with a
wide spectrum of respiratory tract involvement, including
a flulike syndrome, bronchitis, bronchiolitis, and pneu-
monitis (2–5). We report on a patient who died of acute
community-acquired pneumonia, from whom HMPV was
the only pathogen identified.
Case Report
The patient was a 40-year-old Chinese man with previ-
ously good health. He smoked but did not use alcohol. He
lived in Hong Kong and took frequent short business trips
to mainland China. While in Shenzhen in early March
2003, a fever and productive cough with blood-stained
sputum developed. He was hospitalized in Shenzhen and
given intravenous antibiotics (the details of which were
not available). He remained febrile with chills and rigors,
night sweating, and progressive dyspnea. He returned to
Hong Kong and sought treatment at Prince of Wales
Hospital 8 days after the onset of illness. His temperature
was 37.3°C, heart rate 120 beats per minute, blood pres-
sure 110/70 mm Hg, and oxygen saturation 93% on room
air. No skin rash was detected. Air entry over the right
lung had decreased slightly. Chest radiograph showed
patchy consolidations in the right middle zone and mild
infiltrates in the left lower zone. An electrocardiogram
indicated sinus tachycardia with no ischemic changes.
He was admitted to an isolation ward and given supple-
mental oxygen and cefuroxime, 750 mg intravenously
every 8 h. Blood tests showed leukocytosis (leukocyte
count 14.9 x 109/L, reference range [RR] 4.0–10.8 x 109/L)
with neutrophilia (neutrophil count 13.5 x 109/L, 91%; RR
41%–73%) and lymphopenia (lymphocyte count 0.5 x 109/
L, 4%; RR 19%–47%). The hemoglobin and platelet count
and results of renal and liver function tests were unremark-
able. Arterial blood gas while the patient was receiving 2 L
of oxygen showed compensated metabolic acidosis (pH
7.39, RR 7.35–7.45; actual bicarbonate 15 mmol/L, RR
22–26 mmol/L; pO2 14.2 KPa, RR 10.0–13.0 KPa). 
His condition initially improved with normalization of
temperature and heart rate, and a satisfactory level of arte-
rial blood oxygen saturation was maintained until early the
next morning, when he reported increasing dyspnea and
progressed to shock and severe oxygen desaturation.
Before he could be transferred to the intensive care unit, he
underwent cardiorespiratory arrest, and aggressive resusci-
tation attempts were not successful.
Microbiologic Investigations
On admission (8 days after the onset of illness), sputum
and blood samples were taken for routine microscopy, bac-
terial (including Legionella pneumophilia and mycobacte-
ria), and fungal culture. Polymerase chain reactions
(PCRs) targeting Chlamydia pneumoniae, Chlamydia.
psittaci, and Mycoplasma pneumoniae were performed on
the sputum sample.
Nasopharyngeal aspirate was used for virologic investi-
gations. Rapid viral antigen detection by immunofluores-
cence was performed with commercial assays to identify
influenza A and B; parainfluenza 1, 2, and 3; respiratory
syncytial virus (RSV); and adenovirus (Dako Diagnostics
Ltd, Ely, UK, and Chemicon International, Inc., Temecula,
CA). SARS-associated coronavirus (SARS-CoV) was
detected by reverse transcription (RT)-PCR by using
primers COR-1 (sense) 5′ CAC CGT TTC TAC AGG TTA
GCT AAC GA 3′, and COR-2 (antisense) 5′ AAA TGT
TTA CGC AGG TAA GCG TAA AA 3′ that had been
shown to be specific for the novel coronavirus detected
from patients with SARS (6). Virus isolation was per-
formed using rhesus monkey kidney (LLC-MK2), human
laryngeal carcinoma (HEp-2), Mardin Darby canine kid-
ney (MDCK), human embryonic lung fibroblast, Buffalo
green monkey kidney (BGM), and African green monkey
kidney (Vero) monolayers. Cell monolayers were exam-
ined daily for cytopathic effect. After 14 days of incuba-
tion, the growth of influenza A and B, parainfluenza 1, 2,
and 3, RSV, and adenovirus was examined by commercial
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China monoclonal antibodies with the immunofluorescence tech-
nique. In addition, a hemadsorption test was performed for
LLC-MK2 and MDCK monolayers. A shell vial culture
system, coupled with monoclonal antibody–based detec-
tion, was used for the isolation of cytomegalovirus. 
A serum sample taken on admission (8 days after the
onset of illness) was evaluated for hantavirus and atypical
pneumonia serology, including Legionella pneumophila;
M. pneumoniae; C. pneumoniae and psittaci, influenza A
and B; parainfluenza 1, 2, 3; RSV; and adenovirus. In addi-
tion, an in-house immunofluorescence assay based on
SARS-CoV–infected Vero cells was used to detect SARS-
CoV antibodies. This assay has been successfully applied
to specimens from patients with SARS. Results of all
microbiologic investigations were negative. 
Postmortem Findings
Postmortem biopsy specimens were taken from the
lungs, heart, kidney, spleen, small bowel, and muscle.
Pulmonary congestion with edema was noted, but hyaline
membranes had not formed (Figure A). Interstitial inflam-
matory cell infiltration was minimal, and intraalveolar
organizing lesions were rarely seen, whereas detached
atypical pneumocytes were found (Figure B). Atypical
multinucleated pneumocytes were observed, but definite
viral inclusion was not apparent (Figure C). Fibrin throm-
bi were frequently observed in small pulmonary arteries
and arterioles (Figure D). However, no such thrombotic
event was observed in other organs. Central lobular hem-
orrhagic necrosis was noted in the liver. No myocarditis
was observed. Low-grade acute tubular necrosis was seen
in the kidneys. Results of examining other tissues were
unremarkable. No coronavirus particles were seen on
electron microscopy examination of lung cells. The cell
culture results were negative, except that a focal refractile
rounding cytopathic effect developed 12 days after the left
lung tissue sample was injected onto LLC-MK2 cells.
This cytopathic effect progressed slowly to cell detach-
ment, and a similar cytopathic effect was observed on
other areas of the cell monolayer over the next few days.
The cell culture supernatant was positive by an RT-PCR
assay based on primers 5′-GAG TAG GGA TCA TCA
AGC A-3′and 5′-GCT TAG CTG RTATAC AGT GTT-3′,
targeting the F-gene of HMPV. The nucleotide sequence
of the PCR product were identical to the F-gene fragment
of HMPV (GenBank accession no. NC 004148) (1). The
cell culture supernatant was passaged to LLC-MK2 cells,
and the same cytopathic effect was observed after 8 days
of incubation. HMPV particles were shown from the pas-
saged cell culture by electron microscopy. To ascertain the
presence of HMPV infection in this patient, the serum
sample taken on admission (8 days after the onset of ill-
ness) was retrieved for HMPV antibody detection with the
immunofluorescence technique, based on LLC-MK2 cells
infected by the isolated HMPV. An antibody titer of 1:80
was detected.
Conclusions
HMPV is a recently identified human virus associated
with respiratory tract disease. While the full range of clin-
ical features is still being elucidated, several cases of
severe respiratory tract infections have been reported.
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Figure. Pathologic findings of lung tissue sec-
tions. A: Pulmonary congestion and edema
(H&E stain, original magnification x100). B: A
mild degree of interstitial lymphocytic infiltration.
Intra-alveolar organizing exudative lesion was
occasionally found. Detached atypical pneumo-
cytes indicated by arrow (H&E stain, original
magnification x200). C: Atypical multinucleated
pneumocytes were occasionally identified.
Definite viral inclusion was not apparent (H&E
stain, original magnification x400). D: Fibrin
thrombi were frequently noted in small pul-
monary arteries and arterioles (H&E stain, origi-
nal magnification x200). Boivin et al. (2) reported that 3 of 12 infected young
children <5 years of age required intensive care, and a
child with acute leukemia died subsequently. In that study,
one of the six infected adult patients (15–65 years of age)
also required intensive care. In the same study, 2 of 10
infected elderly patients (ages >65 years) died; 1 also had
leukemia and the other had Alzheimer’s disease. However,
none of these patients had an autopsy performed. This
report is the first in which HMPV was the only pathogen
identified from postmortem specimens from a patient with
a fatal respiratory tract disease. 
Our patient had a history of good health and no evi-
dence to suggest that his death was a result of exacerbation
of underlying cardiac or pulmonary conditions.
Coinfection has been found in patients with HMPV-associ-
ated respiratory tract disease (2) and has been suggested to
be a factor influencing clinical outcome (7). In our patient,
no evidence of infection with a copathogen could be
demonstrated. Although the patient had died before a late
convalescent-phase serum sample could be obtained for a
confident exclusion of SARS-CoV infection by serologic
testing, the nasopharyngeal aspirate collected on admis-
sion and the postmortem lung tissue were negative for
SARS-CoV by RT-PCR. The postmortem histologic find-
ings on lung tissue of this patient were different from the
classic picture of virus-associated interstitial pneumonitis.
In addition to the minimal inflammatory cell infiltration,
multinucleated giant cells that might represent viral cyto-
pathic effect were only occasionally seen. Rather, the pre-
dominant histologic finding was the presence of fibrin
thrombi in small pulmonary arteries and arterioles. This
thrombotic event was confined to lung tissue and was not
found in other tissues. Thrombotic vasculopathy has been
observed in infectious diseases caused by HIV,
cytomegalovirus, and herpes viruses (8,9). The clinical
picture usually resembles thrombotic thrombocytopenic
purpura. However, our patient’s condition appeared dis-
tinct. He showed no serologic or morphologic evidence of
other infective agents. He was negative for HIV antibody
and did not fulfill the diagnosis of thrombotic thrombocy-
topenic purpura. The pathogenic event that led to the for-
mation of thrombi was unclear. 
Our patient’s signs and symptoms, together with his his-
tory of travel to southern China, fulfilled the World Health
Organization criteria for a probable case of SARS, but no
evidence of coronavirus infection could be found. The
overall pathologic features of this case were distinct from
those in the series of SARS patients that we had examined
and that were reported by others (10). In SARS patients,
coronavirus particles were seen by electron microscopy in
lung cells of most cases, and the lung injuries consistently
exhibited features of diffuse alveolar damage. Distinctive
airspaces or small airway lesions resembling bronchiolitis
obliterans organizing pneumonia were also detected. These
SARS-associated pathologic features were not observed in
this patient, suggesting a different cause of death. In this
patient, HMPV infection was confirmed by virus isolation
from lung tissue. Although the possibility of HMPV being
a bystander could not be totally excluded, a role of HMPV
in severe respiratory tract disease should not be discount-
ed, particularly in SARS patients that do not show evidence
of coronavirus infection. HMPV has also been detected in
five of the six SARS patients living in Canada; four of
them were coinfected with coronavirus (11). The index
patient of that cluster had stayed in Hong Kong before the
onset of illness. The patient described in this report was
unlikely to have a direct link to the outbreak of SARS in
our hospital. This patient was admitted around the same
time that an outbreak of SARS began in our hospital. That
outbreak mainly involved staff working at the Accident and
Emergency Department and the index ward where a SARS
patient had been treated. The index ward is located on a dif-
ferent floor from where the patient described in this report
was isolated. In addition, neither fever nor respiratory ill-
ness developed in any of the healthcare workers involved
in taking care of this patient in the next 2 weeks, and we
were not aware of any spread to his family members.
Although HMPV and SARS-CoV might differ in trans-
mission efficiency, their role and clinical outcome in acute
respiratory tract disease need to be distinguished. This dis-
tinction is particularly important for analyzing the illness
and death associated with the worldwide outbreak of
SARS. Patients fulfilling the clinical criteria for a probable
case of SARS might be infected by organisms other than
coronavirus.
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